CD126 (IL-6Rα) Antibody, anti-human, REAfinity™
Synonyms: Il6r, IL-6R-1, IL-6RA, IL6Q, IL6RA, IL6RQ, gp80
RECOMBINANT EXTENDED VALIDATION
Bioz Star90/100 Bioz rating
5 Citations
Clone:
REA291 | UV4
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for CD126 (IL-6Rα) Antibody, anti-human, REAfinity™

Flow cytometry applications
APC
Biotin
PE
PE-Vio 615
PE-Vio 770
Vio Bright V423
Recommended dilution:
1:11
Remark:
Cells should be stained prior to fixation, if formaldehyde is used as a fixative.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-104-100, 130-104-138
Description:
Human peripheral blood mononuclear cells (PBMCs) were stained with CD126 (IL-6Rα) as well as with CD3 antibodies and analyzed by flow cytometry using the MACSQuant® Analyzer. Lymphocytes were pre-gated for the analysis. The specificity of the conjugated antibodies is confirmed by blocking the binding to ligand, using pure unconjugated antibodies (control: left image). The Tandem Signal Enhancer has been used to increase binding specificity of tandem-dye–conjugated antibodies. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence or 4',6-diamidino-2-phenylindole (DAPI) fluorescence, as in the case of tandem conjugates.

Application imageView details view details

Application imageView details view details
Extended validation for CD126 (IL-6Rα) Antibody, anti-human, REAfinity™
Specificity
Epitope competition assay

In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.

Other clones
Overlap in epitope recognition with REA291
M5
low
47.7G7.1F2
high
B-R6
low
UV4
high

Cells were incubated with an excess of purified unconjugated CD126 (IL-6Rα) (REA291) antibody followed by staining with fluorochrome-conjugated antibodies from other known clones targeting the same antigen. Fluorescence intensity was then used to assess epitope overlap: a minimal or absent signal indicated high epitope overlap, an intermediate signal suggested partial overlap, and a strong signal reflected low overlap.

Sensitivity
Performance comparison

Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.

Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image

Flow cytometric comparison of different clones for CD126. PBMCs were stained with CD126 antibodies and with a suitable counterstaining. As a control, CD126 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Specifications for CD126 (IL-6Rα) Antibody, anti-human, REAfinity™
Overview

Clone REA291 recognizes the CD126 antigen, a type I cytokine receptor also known as interleukin 6 receptor subunit alpha (IL-6Rα) or membrane glycoprotein 80 (gp80). CD126 associates with the IL-6 receptor β chain (CD130 or gp130) resulting in the formation of a functional high affinity IL-6 receptor (IL-6R) complex. It is also shared by many other receptors like leukemia inhibitory factor (LIF), ciliary neurotropic factor (CNTF), oncostatin M (OSM), IL-11, and cardiotropin 1 (CT-1). CD126 (IL-6Rα) is highly expressed on activated and EBV-transformed B cells, plasma cells, and myeloma cells. Lower expression levels are detected on T cells, monocytes, granulocytes, hepatocytes, epithelial cells, fibroblasts, and neural cells. Interleukin 6 (IL-6) is a potent pleiotropic cytokine that regulates cell growth and differentiation and plays an important role in the immune response. IL-6 binding to the receptor complex results in the stimulation of B and T cells, and hematopoietic precursor proliferation and differentiation. A soluble form of CD126 also exists in human serum. Dysregulated production of IL-6 and the IL-6R are implicated in the pathogenesis of many diseases, such as multiple myeloma, autoimmune diseases, and prostate cancer.

Additional information: Clone REA291 displays negligible binding to Fc receptors.

Alternative names

Il6r, IL-6R-1, IL-6RA, IL6Q, IL6RA, IL6RQ, gp80

Detailed product information

Technical specifications

Clone
REA291
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (S), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human
Antigen
CD126 (IL-6Rα)
Molecular mass of antigen [kDa]
50
Distribution of antigen
B cells, T cells, monocytes, fibroblasts, granulocytes, plasma cells
Entrez Gene ID
RRID
AB_2654805, AB_2654814, AB_2904706, AB_2921857, AB_2654810, AB_2904707, AB_2654813, AB_2654809, AB_2654808, AB_2654806, AB_2654807, AB_2921870

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for CD126 (IL-6Rα) Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

You have previously chosen International as your location.
What do you want to do?